ArticleInternational journal of pharmaceutics2012
Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery.
Article in International journal of pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Protein-based nanoparticles for therapeutic nucleic acid delivery.Biomaterials · 2024Review
- Review
- A comprehensive review of silk-fibroin hydrogels for cell and drug delivery applications in tissue engineering and regenerative medicine.Computational and structural biotechnology journal · 2023Review
- Translational Development of a Silk-Elastinlike Protein Polymer Embolic for Transcatheter Arterial Embolization.Macromolecular bioscience · 2022Article
- Review
- Recent trends in protein and peptide-based biomaterials for advanced drug delivery.Advanced drug delivery reviews · 2020Review
- Article
- Silk Fibroin as a Functional Biomaterial for Drug and Gene Delivery.Pharmaceutics · 2019Review
- Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Artificial Auricular Cartilage Using Silk Fibroin and Polyvinyl Alcohol Hydrogel.International journal of molecular sciences · 2017Article
- In vivo evaluation of matrix metalloproteinase responsive silk-elastinlike protein polymers for cancer gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization.Biomaterials · 2015Article
- Silk-elastin-like protein biomaterials for the controlled delivery of therapeutics.Expert opinion on drug delivery · 2015Review
- Effect of shear on physicochemical properties of matrix metalloproteinase responsive silk-elastinlike hydrogels.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.Gene therapy · 2014Article
- Silk-based biomaterials for sustained drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Controlled release from recombinant polymers.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Designing protein-based biomaterials for medical applications.Acta biomaterialia · 2014Review
- Genetically engineered nanocarriers for drug delivery.International journal of nanomedicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The silk-elastinlike protein polymer, SELP 815K, and poloxomer 407, a commercially available synthetic copolymer, were evaluated to compare their relative performance in matrix-mediated viral gene delivery. Using a xenogenic mouse tumor model of human head and neck squamous cell carcinoma, the efficacy of viral gene-directed enzyme prodrug therapy with these polymers was characterized by viral gene expression in the tumor tissue, tumor size reduction, and survivability with treatment. Viral injection in SELP 815K produced a greater level and more prolonged extent of gene expression in the tumor, a statistically greater tumor size reduction, a longer time until tumor rebound, and a significantly increased survivability, as compared to injection of virus alone or in Poloxamer 407. Safety of treatment with these polymers was evaluated in a non-tumor bearing immunocompetent mouse model. Compared to virus injected alone or in Poloxamer 407, virus injected in SELP 815K had fewer and less severe indications of toxicity related to treatment as assessed by blood analysis, body weight, and histopathology of distant organs and the injection sites. Similar to virus alone or in Poloxamer 407, virus injected in SELP 815K elicited a mild injection site inflammatory response characterized primarily by a mononuclear leukocyte infiltrate and the formation of granulation tissue. Virus injected in SELP 815K resulted in fewer animals with elevated white blood cell counts and a less pronounced local toxicity reaction than was observed with virus in Poloxamer 407. In contrast to virus injected alone or in Poloxamer 407, which were not retained in the injection site tissues beyond week 1, SELP 815K was retained at the injection sites and by the end of the study (week 12), displayed limited absorption, and mild encapsulation. These results demonstrate the benefits of SELP 815K for matrix-mediated gene delivery over the injection of free virus and the injection of virus in Poloxamer 407. Virus in SELP 815K had greater efficacy of tumor suppression, promoted greater levels and greater duration of viral gene expression, and displayed reduced levels of injection site toxicity. Combining these performance and safety benefits with the degree of control with which they can be designed, synthesized and formulated, SELPs continue to show promise for their application in viral gene delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.